Single dose nonavalent HPV vaccine – need of the hour

Abstract

HPV vaccination of the 9-14 years girl children is the answer to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single dose HPV vaccination, antibody titre remains good. Herd immunity also achieved by HPV vaccine. Hence single dose nonavalent HPV vaccination of mass people (sexually naive 9-14 years girl children) can provide almost 100% protections and this will be cost-effective also for developing country.